Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Mizuho Securities USA LLC

Mizuho Securities USA LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 15.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,062 shares of the medical research company’s stock after selling 7,396 shares during the quarter. Mizuho Securities USA LLC’s holdings in Edwards Lifesciences were worth $2,578,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Bank of New York Mellon Corp raised its stake in Edwards Lifesciences by 4.3% during the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after buying an additional 809,605 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after acquiring an additional 2,390,137 shares in the last quarter. AustralianSuper Pty Ltd raised its position in shares of Edwards Lifesciences by 17.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after acquiring an additional 494,604 shares in the last quarter. Ownership Capital B.V. lifted its stake in Edwards Lifesciences by 1.2% during the third quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company’s stock worth $197,509,000 after purchasing an additional 34,597 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in Edwards Lifesciences by 2.1% in the second quarter. American Century Companies Inc. now owns 2,082,961 shares of the medical research company’s stock worth $192,403,000 after purchasing an additional 43,247 shares during the period. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Citigroup dropped their target price on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a report on Tuesday, October 1st. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Finally, Oppenheimer restated an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and a consensus price target of $75.67.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,000 shares of company stock worth $2,657,000. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Trading Up 0.2 %

Shares of Edwards Lifesciences stock opened at $70.49 on Friday. The business has a fifty day simple moving average of $67.70 and a 200-day simple moving average of $75.73. The firm has a market cap of $41.58 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 3.95 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.59 EPS. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.